PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,738,886 | +37.7% | 350,029 | +79.8% | 0.02% | +40.0% |
| Q2 2023 | $7,799,021 | -37.1% | 194,635 | -35.9% | 0.02% | -37.5% |
| Q1 2023 | $12,397,544 | -3.0% | 303,787 | -8.2% | 0.02% | -7.7% |
| Q4 2022 | $12,774,657 | -51.4% | 330,864 | -33.1% | 0.03% | -55.2% |
| Q3 2022 | $26,312,000 | -1.0% | 494,728 | +8.5% | 0.06% | +7.4% |
| Q2 2022 | $26,573,000 | +18.8% | 455,840 | +55.5% | 0.05% | +38.5% |
| Q1 2022 | $22,367,000 | +183.1% | 293,104 | +123.2% | 0.04% | +200.0% |
| Q4 2021 | $7,901,000 | +4036.6% | 131,347 | +3737.2% | 0.01% | – |
| Q3 2021 | $191,000 | +29.1% | 3,423 | +39.8% | 0.00% | – |
| Q2 2021 | $148,000 | -13.5% | 2,448 | 0.0% | 0.00% | – |
| Q1 2021 | $171,000 | -25.7% | 2,448 | -36.1% | 0.00% | – |
| Q3 2020 | $230,000 | -93.6% | 3,828 | -94.4% | 0.00% | -100.0% |
| Q2 2020 | $3,576,000 | +57.2% | 68,221 | +0.4% | 0.01% | +33.3% |
| Q1 2020 | $2,275,000 | +265.2% | 67,937 | +392.4% | 0.01% | +500.0% |
| Q4 2019 | $623,000 | +50.5% | 13,797 | +27.0% | 0.00% | 0.0% |
| Q3 2019 | $414,000 | -56.6% | 10,861 | -50.4% | 0.00% | -50.0% |
| Q2 2019 | $953,000 | -75.0% | 21,916 | -78.2% | 0.00% | -71.4% |
| Q1 2019 | $3,819,000 | -41.5% | 100,358 | -33.9% | 0.01% | -53.3% |
| Q4 2018 | $6,528,000 | +119.8% | 151,876 | +150.1% | 0.02% | +150.0% |
| Q3 2018 | $2,970,000 | +63.8% | 60,715 | +7.3% | 0.01% | +50.0% |
| Q2 2018 | $1,813,000 | +17.9% | 56,610 | +14.7% | 0.00% | +33.3% |
| Q1 2018 | $1,538,000 | +11.6% | 49,361 | +62.7% | 0.00% | +50.0% |
| Q4 2017 | $1,378,000 | +46.6% | 30,330 | +21.0% | 0.00% | 0.0% |
| Q3 2017 | $940,000 | -93.0% | 25,057 | -91.2% | 0.00% | -91.7% |
| Q2 2017 | $13,524,000 | +3775.1% | 283,513 | +3599.8% | 0.02% | +2300.0% |
| Q1 2017 | $349,000 | +36.3% | 7,663 | -6.2% | 0.00% | – |
| Q4 2016 | $256,000 | – | 8,167 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |